These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 21980965

  • 1. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.
    Cousins D, Topping K, Lee V, Sweeney J, Lawton M.
    Drug Metabol Drug Interact; 2011; 26(3):139-41. PubMed ID: 21980965
    [Abstract] [Full Text] [Related]

  • 2. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
    Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V.
    Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
    [Abstract] [Full Text] [Related]

  • 3. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group.
    AIDS; 2010 Jul 17; 24(11):1697-707. PubMed ID: 20467288
    [Abstract] [Full Text] [Related]

  • 4. [Renal transplantation in HIV-infected patients in Spain].
    Mazuecos A, Pascual J, Gómez E, Sola E, Cofán F, López F, Puig-Hooper CE, Baltar JM, González-Molina M, Oppenheimer F, Marcén R, Rivero M.
    Nefrologia; 2006 Jul 17; 26(1):113-20. PubMed ID: 16649432
    [Abstract] [Full Text] [Related]

  • 5. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV, Hesse K, Amin J, Cooper DA.
    Antivir Ther; 2010 Jul 17; 15(7):1035-8. PubMed ID: 21041919
    [Abstract] [Full Text] [Related]

  • 6. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar 17; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 7. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug 17; 17(96):135-7. PubMed ID: 19480091
    [Abstract] [Full Text] [Related]

  • 8. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
    Wandeler G, Furrer H, Rauch A.
    AIDS; 2011 Nov 28; 25(18):2306-8. PubMed ID: 22067200
    [No Abstract] [Full Text] [Related]

  • 9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 28; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 10. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.
    Bickel M, Anadol E, Vogel M, Hofmann WP, von Hentig N, Kuetscher J, Kurowski M, Moench C, Lennemann T, Lutz T, Bechstein WO, Brodt HR, Rockstroh J.
    J Antimicrob Chemother; 2010 May 28; 65(5):999-1004. PubMed ID: 20202988
    [Abstract] [Full Text] [Related]

  • 11. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, Ragni M, Fung JJ.
    Liver Transpl; 2002 Sep 28; 8(9):841-5. PubMed ID: 12200788
    [Abstract] [Full Text] [Related]

  • 12. The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.
    Cocohoba J.
    Expert Rev Anti Infect Ther; 2009 Dec 28; 7(10):1159-63. PubMed ID: 19968507
    [Abstract] [Full Text] [Related]

  • 13. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
    Di Biagio A, Rosso R, Siccardi M, D'Avolio A, Bonora S, Viscoli C.
    J Antimicrob Chemother; 2009 Oct 28; 64(4):874-5. PubMed ID: 19643773
    [No Abstract] [Full Text] [Related]

  • 14. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.
    Mertz D, Battegay M, Marzolini C, Mayr M.
    Am J Kidney Dis; 2009 Jul 28; 54(1):e1-4. PubMed ID: 19346040
    [Abstract] [Full Text] [Related]

  • 15. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.
    van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD.
    Transplantation; 2013 Jan 27; 95(2):397-402. PubMed ID: 23250333
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 17. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C, Gulick RM.
    Clin Infect Dis; 2009 Apr 01; 48(7):931-9. PubMed ID: 19231980
    [Abstract] [Full Text] [Related]

  • 18. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar 01; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 01; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 01; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.